Why the study?
Diabetes increases heart failure risk and is highly prevalent in HFpEF, but the role of tissue factor in diabetes-induced cardiac inflammation, hypertrophy, and heart failure has not been studied.
Does tissue factor deficiency prevent cardiac inflammation, hypertrophy, and HFpEF in a mouse model of type 1 diabetes?
Does tissue factor deficiency prevent cardiac inflammation, hypertrophy, and HFpEF in a mouse model of type 1 diabetes?
Tissue factor plays a critical role in mediating diabetes-induced cardiac inflammation, hypertrophy, and HFpEF in a mouse model, suggesting a potential novel therapeutic target.
May link tissue factor to diabetes-related cardiac inflammation; hypothesis-generating and requires validation before clinical consideration.
Patients with diabetes have an increased risk of heart failure (HF). Diabetes is highly prevalent in HF with preserved ejection fraction (HFpEF), which is on the rise worldwide. The role of diabetes in HF is less established, and available treatments for HF are not effective in patients with HFpEF. Tissue factor (TF), a transmembrane receptor, plays an important role in immune cell inflammation and atherothrombosis in diabetes. However, its role in diabetes-induced cardiac inflammation, hypertrophy, and HF has not been studied. In this study, we used wild-type (WT), heterozygous, and low-TF (with 1% human TF) mice to determine the role of TF in type 1 diabetes-induced HF. We found significant upregulation of cardiac TF mRNA and protein levels in diabetic WT hearts compared with nondiabetic controls. WT diabetic hearts also exhibited increased inflammation and cardiac hypertrophy versus controls. However, these changes in cardiac inflammation and hypertrophy were not found in low-TF mice with diabetes compared with their nondiabetic controls. TF deficiency was also associated with improved cardiac function parameters suggestive of HFpEF, which was evident in WT mice with diabetes. The TF regulation of inflammation and cardiac remodeling was further dependent on downstream ERK1/2 and STAT3 pathways. In summary, our study demonstrated an important role of TF in regulating diabetes-induced inflammation, hypertrophy, and remodeling of the heart leading to HFpEF.
No takes yet. Share an insight, caveat, or question.
Cibi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: